Deferred Revenue (Tables)

3 Months Ended

Mar. 31, 2023

Summary of Percentages of Deferred Revenue by Year

As of March 31, 2023, the Company expects to recognize approximately the following percentages of deferred revenue by year:

	Revenue
Year:	Recognition
Remainder of 2023	61	%
2024	29	%
2025	9	%
2026	1	%
Total	100	%

Summary of Revenue Generated in Geographic Regions for Years Indicated

	Revenues by Geography
	Three Months Ended March 31,
	2023				2022
			% of				% of
	Amount		Revenues		Amount		Revenues
	(in thousands, except percentages)
United States	$	14,964	96	%	$	13,517	95	%
International		576	4	%		664	5	%
Total revenues	$	15,540	100	%	$	14,181	100	%

United States

Summary of Revenue Generated in Product Category for Years Indicated

	U.S. Revenues by Product Category
	Three Months Ended March 31,
	2023				2022
			% of				% of
	Amount		Revenues		Amount		Revenues
	(in thousands, except percentages)
NeuroStar Advanced Therapy system	$	3,850	26	%	$	3,642	27	%
Treatment sessions		10,643	71	%		9,469	70	%
Other		471	3	%		406	3	%
Total U.S. revenues	$	14,964	100	%	$	13,517	100	%

International

Summary of Revenue Generated in Product Category for Years Indicated

	U.S. Revenues by Product Category
	Three Months Ended March 31,
	2023				2022
			% of				% of
	Amount		Revenues		Amount		Revenues
	(in thousands, except percentages)
NeuroStar Advanced Therapy system	$	3,850	26	%	$	3,642	27	%
Treatment sessions		10,643	71	%		9,469	70	%
Other		471	3	%		406	3	%
Total U.S. revenues	$	14,964	100	%	$	13,517	100	%

	International Revenues by Product Category
	Three Months Ended March 31,
	2023				2022
			% of				% of
	Amount		Revenues		Amount		Revenues
	(in thousands, except percentages)
NeuroStar Advanced Therapy System	$	259	45	%	$	313	47	%
Treatment sessions		184	32	%		170	26	%
Other		133	23	%		181	27	%
Total international revenues	$	576	100	%	$	664	100	%